Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 12:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Conditions
Percutaneous Coronary Intervention
Interventions
Iopamidol, adenosine, Navvus® Catheter, CVi® Contrast Delivery System
Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Long Beach, California • Coon Rapids, Minnesota • Minneapolis, Minnesota + 2 more
Conditions
Contrast Induced Nephropathy
Interventions
Iopamidol 370 mgI/mL
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Healthy
Interventions
Ioforminol 160 mgI/mL, Ioforminol 200 mgI/mL, Iopamidol 300 mgI/mL
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Non-Obstructive Coronary Atherosclerosis
Interventions
Coronary computed tomography angiography (CCTA), Isovue, Nitroglycerin, Metoprolol
Procedure · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 125 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Urothelial Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
Isovue-M 200
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Completed Phase 2 Interventional Results available

Coronary MDCTA With Iopamidol Injection 370

NCT00558792
Conditions
Coronary Artery Disease
Interventions
Isovue 370, 70 mL, Isovue 370, 80 mL, Isovue 370, 90 mL
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
30 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
CIN
Interventions
Iopamidol 370 mgI/mL
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Drug Safety
Interventions
Iodixanol, Iopamidol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Renal Insufficiency, Diabetes Mellitus
Interventions
Iodixanol 320-Arm 1, Iopamidol 300-Arm 2
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Chronic Renal Insufficiency, Diabete Mellitus, Congestive Heart Failure
Interventions
GE-145
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
65 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Princeton, New Jersey
Terminated Phase 4 Interventional Results available

Double-Blind Placebo-Controlled CIN Trial

NCT02467075
Conditions
Acute Kidney Injury
Interventions
Iopamidol 300 (Contrast), Placebo (Normal Saline)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Kidney Disease
Interventions
Blood work
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Phase 4 Interventional Results available

Kidney Damage in Patients With Normal eGFR

NCT01137786
Conditions
Coronary Artery Stenosis
Interventions
Non ionic contrast media comparator
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Springfield, Illinois
Conditions
Pulmonary Embolism
Interventions
Isovue
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Princeton, New Jersey
Completed Phase 4 Interventional Results available

Thoracoabdominal Arortic CTA Study

NCT02291718
Conditions
Thoracic Aortic Aneurysm
Interventions
Isovue
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Coronary Artery Disease, Ischemia
Interventions
Computed Tomography Angiography
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Malignant Lung Neoplasm, Metastatic Malignant Neoplasm in the Lung, Non-Small Cell Lung Carcinoma, Stage IV Lung Cancer
Interventions
CAPP-Seq, Isovue-200, Computed Tomography Perfusion Imaging
Device · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Malignant Solid Neoplasm
Interventions
Advanced Magnetic Resonance Imaging, Conventional Magnetic Resonance Imaging, Gadolinium-Chelate, Iopamidol
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Completed Not applicable Interventional Accepts healthy volunteers

ISOVUE Comparative Trial

NCT07363759
Conditions
Lumbar Degenerative Disease, Lumbar Degenerative Disc Disease, Degenerative Spine
Interventions
ISOVUE 300 Observation, ISOVUE 300 Feedback
Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Completed Not applicable Interventional Results available

Myocardial Stress Perfusion Imaging With Dual Source CT

NCT00853671
Conditions
Coronary Artery Disease
Interventions
Adenosine Stress Dual-source CTP
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Contrast Agents During CT Angiography

NCT01534975
Conditions
Contrast Enhancement on Cardiac CT
Interventions
contrast agent
Diagnostic Test
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
513 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Torrance, California
Conditions
Breast Cancer
Interventions
CEST MRI
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Chronic Renal Impairment, Diabetes Mellitus
Interventions
Iopamidol injection 76%, iodixanol
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Patient Comfort and Safety
Interventions
Iodixanol, Iopamidol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Princeton, New Jersey